Keyword Connections

•  W. Rathmell

Resources

• No matching connections

Communities

• No matching connections

Publications

• Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
  Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M
  (2012) N Engl J Med 366: 2443-54
• Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.
  Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L, Motzer RJ, Global ARCC Trial
  (2007) N Engl J Med 356: 2271-81
• VHL substrate transcription factor ZHX2 as an oncogenic driver in clear cell renal cell carcinoma.
  Zhang J, Wu T, Simon J, Takada M, Saito R, Fan C, Liu XD, Jonasch E, Xie L, Chen X, Yao X, Teh BT, Tan P, Zheng X, Li M, Lawrence C, Fan J, Geng J, Liu X, Hu L, Wang J, Liao C, Hong K, Zurlo G, Parker JS, Auman JT, Perou CM, Rathmell WK, Kim WY, Kirschner MW, Kaelin WG, Baldwin AS, Zhang Q
  (2018) Science 361: 290-295
• Analysis of Drosophila segmentation network identifies a JNK pathway factor overexpressed in kidney cancer.
  Liu J, Ghanim M, Xue L, Brown CD, Iossifov I, Angeletti C, Hua S, Nègre N, Ludwig M, Stricker T, Al-Ahmadie HA, Tretiakova M, Camp RL, Perera-Alberto M, Rimm DL, Xu T, Rzhetsky A, White KP
  (2009) Science 323: 1218-22
• Individualised axitinib regimen for patients with metastatic renal cell carcinoma after treatment with checkpoint inhibitors: a multicentre, single-arm, phase 2 study.
  Ornstein MC, Pal SK, Wood LS, Tomer JM, Hobbs BP, Jia XS, Allman KD, Martin A, Olencki T, Davis NB, Gilligan TD, Mortazavi A, Rathmell WK, Garcia JA, Rini BI
  (2019) Lancet Oncol 20: 1386-1394
• Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation.
  Kapur P, Peña-Llopis S, Christie A, Zhrebker L, Pavía-Jiménez A, Rathmell WK, Xie XJ, Brugarolas J
  (2013) Lancet Oncol 14: 159-167
• The somatic genomic landscape of chromophobe renal cell carcinoma.
  Davis CF, Ricketts CJ, Wang M, Yang L, Cherniack AD, Shen H, Buhay C, Kang H, Kim SC, Fahey CC, Hacker KE, Bhanot G, Gordenin DA, Chu A, Gunaratne PH, Biehl M, Seth S, Kaipparettu BA, Bristow CA, Donehower LA, Wallen EM, Smith AB, Tickoo SK, Tamboli P, Reuter V, Schmidt LS, Hsieh JJ, Choueiri TK, Hakimi AA, The Cancer Genome Atlas Research Network, Chin L, Meyerson M, Kucherlapati R, Park WY, Robertson AG, Laird PW, Henske EP, Kwiatkowski DJ, Park PJ, Morgan M, Shuch B, Muzny D, Wheeler DA, Linehan WM, Gibbs RA, Rathmell WK, Creighton CJ
  (2014) Cancer Cell 26: 319-330
• SPOP promotes tumorigenesis by acting as a key regulatory hub in kidney cancer.
  Li G, Ci W, Karmakar S, Chen K, Dhar R, Fan Z, Guo Z, Zhang J, Ke Y, Wang L, Zhuang M, Hu S, Li X, Zhou L, Li X, Calabrese MF, Watson ER, Prasad SM, Rinker-Schaeffer C, Eggener SE, Stricker T, Tian Y, Schulman BA, Liu J, White KP
  (2014) Cancer Cell 25: 455-68
• HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma.
  Gordan JD, Lal P, Dondeti VR, Letrero R, Parekh KN, Oquendo CE, Greenberg RA, Flaherty KT, Rathmell WK, Keith B, Simon MC, Nathanson KL
  (2008) Cancer Cell 14: 435-46
• Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma.
  McDermott DF, Huseni MA, Atkins MB, Motzer RJ, Rini BI, Escudier B, Fong L, Joseph RW, Pal SK, Reeves JA, Sznol M, Hainsworth J, Rathmell WK, Stadler WM, Hutson T, Gore ME, Ravaud A, Bracarda S, Suárez C, Danielli R, Gruenwald V, Choueiri TK, Nickles D, Jhunjhunwala S, Piault-Louis E, Thobhani A, Qiu J, Chen DS, Hegde PS, Schiff C, Fine GD, Powles T
  (2018) Nat Med 24: 749-757
• Neoadjuvant clinical trial with sorafenib for patients with stage II or higher renal cell carcinoma.
  Cowey CL, Amin C, Pruthi RS, Wallen EM, Nielsen ME, Grigson G, Watkins C, Nance KV, Crane J, Jalkut M, Moore DT, Kim WY, Godley PA, Whang YE, Fielding JR, Rathmell WK
  (2010) J Clin Oncol 28: 1502-7
• Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma.
  Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, Negrier S, Szczylik C, Pili R, Bjarnason GA, Garcia-del-Muro X, Sosman JA, Solska E, Wilding G, Thompson JA, Kim ST, Chen I, Huang X, Figlin RA
  (2009) J Clin Oncol 27: 3584-90
• Incidence and risk of congestive heart failure in patients with renal and nonrenal cell carcinoma treated with sunitinib.
  Richards CJ, Je Y, Schutz FA, Heng DY, Dallabrida SM, Moslehi JJ, Choueiri TK
  (2011) J Clin Oncol 29: 3450-6
• Multi-institutional study of the angiogenesis inhibitor TNP-470 in metastatic renal carcinoma.
  Stadler WM, Kuzel T, Shapiro C, Sosman J, Clark J, Vogelzang NJ
  (1999) J Clin Oncol 17: 2541-5
• Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma.
  McDermott DF, Regan MM, Clark JI, Flaherty LE, Weiss GR, Logan TF, Kirkwood JM, Gordon MS, Sosman JA, Ernstoff MS, Tretter CP, Urba WJ, Smith JW, Margolin KA, Mier JW, Gollob JA, Dutcher JP, Atkins MB
  (2005) J Clin Oncol 23: 133-41
• Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib.
  Hainsworth JD, Sosman JA, Spigel DR, Edwards DL, Baughman C, Greco A
  (2005) J Clin Oncol 23: 7889-96
• Phase IB clinical trial of anti-CD3 followed by high-dose bolus interleukin-2 in patients with metastatic melanoma and advanced renal cell carcinoma: clinical and immunologic effects.
  Sosman JA, Weiss GR, Margolin KA, Aronson FR, Sznol M, Atkins MB, O'Boyle K, Fisher RI, Boldt DH, Doroshow J
  (1993) J Clin Oncol 11: 1496-505
• Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: a University of Chicago Phase II Consortium study.
  Stadler WM, Vogelzang NJ, Amato R, Sosman J, Taber D, Liebowitz D, Vokes EE
  (2000) J Clin Oncol 18: 371-5
• Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer.
  Gollob JA, Rathmell WK, Richmond TM, Marino CB, Miller EK, Grigson G, Watkins C, Gu L, Peterson BL, Wright JJ
  (2007) J Clin Oncol 25: 3288-95
• Phase II Study of Two Weeks on, One Week off Sunitinib Scheduling in Patients With Metastatic Renal Cell Carcinoma.
  Jonasch E, Slack RS, Geynisman DM, Hasanov E, Milowsky MI, Rathmell WK, Stovall S, Juarez D, Gilchrist TR, Pruitt L, Ornstein MC, Plimack ER, Tannir NM, Rini BI
  (2018) J Clin Oncol 36: 1588-1593
• Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.
  Rini BI, Michaelson MD, Rosenberg JE, Bukowski RM, Sosman JA, Stadler WM, Hutson TE, Margolin K, Harmon CS, DePrimo SE, Kim ST, Chen I, George DJ
  (2008) J Clin Oncol 26: 3743-8
• Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial.
  Clark JI, Atkins MB, Urba WJ, Creech S, Figlin RA, Dutcher JP, Flaherty L, Sosman JA, Logan TF, White R, Weiss GR, Redman BG, Tretter CP, McDermott D, Smith JW, Gordon MS, Margolin KA
  (2003) J Clin Oncol 21: 3133-40
• In vivo HIF-mediated reductive carboxylation is regulated by citrate levels and sensitizes VHL-deficient cells to glutamine deprivation.
  Gameiro PA, Yang J, Metelo AM, Pérez-Carro R, Baker R, Wang Z, Arreola A, Rathmell WK, Olumi A, López-Larrubia P, Stephanopoulos G, Iliopoulos O
  (2013) Cell Metab 17: 372-85
• Variation in chromatin accessibility in human kidney cancer links H3K36 methyltransferase loss with widespread RNA processing defects.
  Simon JM, Hacker KE, Singh D, Brannon AR, Parker JS, Weiser M, Ho TH, Kuan PF, Jonasch E, Furey TS, Prins JF, Lieb JD, Rathmell WK, Davis IJ
  (2014) Genome Res 24: 241-50
• Pleiotropic effects of the trichloroethylene-associated P81S VHL mutation on metabolism, apoptosis, and ATM-mediated DNA damage response.
  Desimone MC, Rathmell WK, Threadgill DW
  (2013) J Natl Cancer Inst 105: 1355-64
• Repetitive weekly cycles of recombinant human interleukin-2: responses of renal carcinoma with acceptable toxicity.
  Sosman JA, Kohler PC, Hank J, Moore KH, Bechhofer R, Storer B, Sondel PM
  (1988) J Natl Cancer Inst 80: 60-3
• Alterations in NFkappaB activation in T lymphocytes of patients with renal cell carcinoma.
  Uzzo RG, Clark PE, Rayman P, Bloom T, Rybicki L, Novick AC, Bukowski RM, Finke JH
  (1999) J Natl Cancer Inst 91: 718-21
• Hypoxia, angiogenesis, and metabolism in the hereditary kidney cancers.
  Chappell JC, Payne LB, Rathmell WK
  (2019) J Clin Invest 129: 442-451
• Renal cell carcinoma-derived gangliosides suppress nuclear factor-kappaB activation in T cells.
  Uzzo RG, Rayman P, Kolenko V, Clark PE, Cathcart MK, Bloom T, Novick AC, Bukowski RM, Hamilton T, Finke JH
  (1999) J Clin Invest 104: 769-76
• Endogenous retroviral signatures predict immunotherapy response in clear cell renal cell carcinoma.
  Smith CC, Beckermann KE, Bortone DS, De Cubas AA, Bixby LM, Lee SJ, Panda A, Ganesan S, Bhanot G, Wallen EM, Milowsky MI, Kim WY, Rathmell WK, Swanstrom R, Parker JS, Serody JS, Selitsky SR, Vincent BG
  (2018) J Clin Invest 128: 4804-4820
• Editorial comment on: Vaccine therapy in patients with renal cell carcinoma.
  Clark PE
  (2009) Eur Urol 55: 1343-4
• Reply to Alexander S. Parker, Brad C. Leibovich, Jeanette E. Eckel-Passow, John C. Cheville's letter to the editor re: Samira A. Brooks, A. Rose Brannon, Joel S. Parker, et al. ClearCode34: a prognostic risk predictor for localized clear cell renal cell carcinoma. Eur Urol 2014;66:77-84.
  Rathmell WK, Brooks SA, Parker JS, Nielsen ME
  (2014) Eur Urol 66: e92
• Preoperative nutritional status is an important predictor of survival in patients undergoing surgery for renal cell carcinoma.
  Morgan TM, Tang D, Stratton KL, Barocas DA, Anderson CB, Gregg JR, Chang SS, Cookson MS, Herrell SD, Smith JA, Clark PE
  (2011) Eur Urol 59: 923-8
• ClearCode34: A prognostic risk predictor for localized clear cell renal cell carcinoma.
  Brooks SA, Brannon AR, Parker JS, Fisher JC, Sen O, Kattan MW, Hakimi AA, Hsieh JJ, Choueiri TK, Tamboli P, Maranchie JK, Hinds P, Miller CR, Nielsen ME, Rathmell WK
  (2014) Eur Urol 66: 77-84
• Basic research in kidney cancer.
  Oosterwijk E, Rathmell WK, Junker K, Brannon AR, Pouliot F, Finley DS, Mulders PF, Kirkali Z, Uemura H, Belldegrun A
  (2011) Eur Urol 60: 622-33
• Meta-analysis of clear cell renal cell carcinoma gene expression defines a variant subgroup and identifies gender influences on tumor biology.
  Brannon AR, Haake SM, Hacker KE, Pruthi RS, Wallen EM, Nielsen ME, Rathmell WK
  (2012) Eur Urol 61: 258-68
• Targeting of the VHL-hypoxia-inducible factor-hypoxia-induced gene pathway for renal cell carcinoma therapy.
  Sosman JA
  (2003) J Am Soc Nephrol 14: 2695-702
• HNF1B Loss Exacerbates the Development of Chromophobe Renal Cell Carcinomas.
  Sun M, Tong P, Kong W, Dong B, Huang Y, Park IY, Zhou L, Liu XD, Ding Z, Zhang X, Bai S, German P, Powell R, Wang Q, Tong X, Tannir NM, Matin SF, Rathmell WK, Fuller GN, McCutcheon IE, Walker CL, Wang J, Jonasch E
  (2017) Cancer Res 77: 5313-5326
• Haploinsufficiency for Microtubule Methylation Is an Early Driver of Genomic Instability in Renal Cell Carcinoma.
  Chiang YC, Park IY, Terzo EA, Tripathi DN, Mason FM, Fahey CC, Karki M, Shuster CB, Sohn BH, Chowdhury P, Powell RT, Ohi R, Tsai YS, de Cubas AA, Khan A, Davis IJ, Strahl BD, Parker JS, Dere R, Walker CL, Rathmell WK
  (2018) Cancer Res 78: 3135-3146
• The VHL tumor suppressor and HIF: insights from genetic studies in mice.
  Kapitsinou PP, Haase VH
  (2008) Cell Death Differ 15: 650-9